Indisulam (Synonyms: E-7070) |
| カタログ番号GC65549 |
Indisulam (E 7070) は、抗がん作用を持つ炭酸脱水酵素阻害剤です。 Indisulam (E 7070) は、細胞周期の G1 期を標的とするスルホンアミド剤です。 Indisulam (E 7070) は、CDK2 とサイクリン E の両方の活性化を阻害することにより、G1/S 移行の遮断を引き起こします。Indisulam (E 7070) は、DCAF15 への動員を介して RBM39 の分解を誘導することにより、スプライシングを標的にします。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 165668-41-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15[1][2].
Indisulam (E7070, 0-50 μg/mL, 12-48 h) causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death[1].
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models[1].
[1]. Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37(17):2275-82.
[2]. Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *